RVU Stock Overview A biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ryvu Therapeutics S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ryvu Therapeutics Historical stock prices Current Share Price zł36.50 52 Week High zł61.80 52 Week Low zł36.00 Beta 0.65 1 Month Change -20.65% 3 Month Change -32.66% 1 Year Change -39.17% 3 Year Change -39.07% 5 Year Change -19.43% Change since IPO 575.93%
Recent News & Updates
Ryvu Therapeutics provides an update on RVU120 Phase II program Dec 12
The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More Dec 07
Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) Dec 05
New major risk - Revenue and earnings growth Nov 27
New minor risk - Share price stability Nov 14
Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023) Nov 08 See more updates
Ryvu Therapeutics provides an update on RVU120 Phase II program Dec 12
The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More Dec 07
Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) Dec 05
New major risk - Revenue and earnings growth Nov 27
New minor risk - Share price stability Nov 14
Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023) Nov 08
Ryvu Therapeutics Announces Dosing of the First Patient in the Remark Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Sep 19
New major risk - Financial position Sep 12
Second quarter 2024 earnings released: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023) Sep 12
Price target increased by 8.5% to zł77.95 Jun 18
Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024 May 31
First quarter 2024 earnings released: zł0.80 loss per share (vs zł0.79 loss in 1Q 2023) May 17
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 13
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting Mar 06
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS Feb 15
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml Feb 01 Ryvu Therapeutics S.A. to Report Q1, 2024 Results on May 15, 2024
New minor risk - Share price stability Dec 12
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023 Dec 08
Third quarter 2023 earnings released Nov 30
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120 Oct 23
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt Oct 20
Second quarter 2023 earnings released Sep 15
New major risk - Financial position Sep 15
Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023 May 23
First quarter 2023 earnings released May 18
Price target increased by 13% to zł72.23 Mar 30
Price target increased by 8.7% to zł63.80 Feb 02 Ryvu Therapeutics S.A. to Report Q3, 2023 Results on Nov 29, 2023
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting Dec 13
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting Nov 04
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium Oct 27 Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.9 million in funding Oct 07
Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm Aug 18
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate Aug 02
Ryvu Therapeutics Announces Executive Changes Jul 27
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress Jun 11
Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022 Jun 08
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 22
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 At the 2022 European Hematology Association Congress May 13
Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology Annual Meeting Apr 28
Full year 2021 earnings: Revenues exceed analyst expectations Mar 15
Now 20% undervalued after recent price drop Feb 18
Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%? Jan 25
Now 20% undervalued after recent price drop Jan 24
Ryvu Therapeutics S.A. Presents Clinical and Translational Data Updates At the 63rd American Society of Hematology Annual Meeting and the 44Th San Antonio Breast Cancer Symposium Dec 15
Third quarter 2021 earnings released Nov 13
Second quarter 2021 earnings released Sep 09
Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors Aug 27
Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical Trial of RVU120 in Acute Myeloid Leukemia and Myelodysplastic Syndrome Jul 15
Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel24 Presented by Development Partner Menarini Jun 12
Ryvu Therapeutics Announces Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021 Jun 02
Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 (Sel120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors in Poland May 29
First quarter 2021 earnings released May 16
Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association May 13
Full year 2020 earnings released Mar 18
Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug Mar 10
What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares? Feb 05
Ryvu Therapeutics S.A. to Report First Half, 2021 Results on Sep 08, 2021 Jan 16 Ryvu Therapeutics S.A. to Report Q3, 2021 Results on Nov 10, 2021
Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return Dec 14
New 90-day low: zł49.00 Dec 04
New 90-day low: zł52.00 Oct 21
First half earnings released Sep 29
New 90-day low: zł58.80 Sep 26
Ryvu Therapeutics S.A. Announces That the First Patient Has Been Treated in Europe for the Cohort Expansion Part of Phase Ii Diamond-01 Clinical Trial (Cli24-001; Nct03008187) Sep 17
New 90-day low - zł60.00 Aug 27
Ryvu Therapeutics S.A. has completed a Follow-on Equity Offering in the amount of PLN 143.0547 million. Jul 23 Shareholder Returns RVU PL Life Sciences PL Market 7D -25.3% -14.5% -2.5% 1Y -39.2% -26.1% -4.5%
See full shareholder returns
Return vs Market: RVU underperformed the Polish Market which returned -5.2% over the past year.
Price Volatility Is RVU's price volatile compared to industry and market? RVU volatility RVU Average Weekly Movement 8.4% Life Sciences Industry Average Movement 7.2% Market Average Movement 4.9% 10% most volatile stocks in PL Market 8.6% 10% least volatile stocks in PL Market 3.3%
Stable Share Price: RVU's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: RVU's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company Founded Employees CEO Website 2007 270 Pawel Przewiezlikowski ryvu.com
Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia.
Show more Ryvu Therapeutics S.A. Fundamentals Summary How do Ryvu Therapeutics's earnings and revenue compare to its market cap? RVU fundamental statistics Market cap zł843.89m Earnings (TTM ) -zł104.14m Revenue (TTM ) zł91.18m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RVU income statement (TTM ) Revenue zł91.18m Cost of Revenue zł18.68m Gross Profit zł72.50m Other Expenses zł176.63m Earnings -zł104.14m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.50 Gross Margin 79.51% Net Profit Margin -114.21% Debt/Equity Ratio 45.3%
How did RVU perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 05:01 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamil Kliszcz Biuro maklerskie mBanku Beata Szparaga-Wasniewska Biuro maklerskie mBanku Jonas Peciulis Edison Investment Research
Show 6 more analysts 
